NASDAQ · Biotechnology

VNDA (VNDA) Stock

$5.22 +0.77% NASDAQ: VNDA Healthcare

Valuation

MetricValue
Price$5.22
Market Cap$313.91M
P/E Ratio-1.65
P/B Ratio1.14
P/S Ratio1.71
EPS (TTM)$-3.74
52-Week High$9.94
52-Week Low$4.14
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-67.28%
ROA-44.99%
ROCE-46.18%
Gross Margin-69.91%
Operating Margin-69.91%
Net Margin-1.10%
Debt/Equity0.05
Current Ratio2.39

Annual Financials (USD)

Metric20212022202320242025
Revenue$269.0M$254.0M$193.0M$199.0M$216.0M
Operating Profit$42.0M$6.0M$-14.0M$-41.0M$-151.0M
Net Profit$33.0M$6.0M$3.0M$-19.0M$-220.0M
EPS$0.58$0.11$0.04$-0.32$-3.74
Op Margin15.7%2.5%-7.2%-20.5%-70.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$594.0M$634.0M$648.0M$656.0M$489.0M
Total Liabilities$89.0M$107.0M$104.0M$118.0M$162.0M
Cash$52.0M$135.0M$136.0M$102.0M$85.0M
Borrowings$12.0M$11.0M$9.0M$12.0M$13.0M

Latest News

Vanda Reports Positive Opinion for Imsidolimab Orphan Drug Label MT Newswires · Jul 16, 2026 Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe PR Newswire · Jul 16, 2026 NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PR Newswire · Jul 15, 2026 Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit PR Newswire · Jul 10, 2026 VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy Stocktwits · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$64.0M$32.0M$13.0M$-16.0M$-109.0M
Investing Cash Flow$-77.0M$49.0M$-12.0M$-18.0M$94.0M
Financing Cash Flow$0$0$0$0$-1.0M
Net Cash Flow$-9.0M$83.0M$1.0M$-34.0M$-17.0M
Free Cash Flow$64.0M$31.0M$12.0M$-16.0M$-110.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-34.09%
Quick Ratio2.15
Interest Coverage—
Return 1Y10.74%
Return 3Y-16.64%
Return 5Y-69.77%

Ownership

Insiders Held6.65%
Institutions Held78.81%
Institutions Float Held84.43%
Institutional HolderSharesReport Date
Blackrock Inc.7,275,9882026-03-31
Renaissance Technologies, LLC3,759,5592026-03-31
State Street Corporation3,015,5622026-03-31
AIGH Capital Management LLC2,750,0002026-03-31
Vanguard Capital Management LLC2,481,4912026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHV $6.66 +2.94% -4.63 $683.71M 0.00%
ALLO $1.95 +2.63% -2.17 $673.05M 0.00%
ARCT $6.26 +0.64% -2.93 $177.93M 0.00%
AVIR $4.75 +1.06% -2.13 $380.13M 0.00%
CAPR $3.93 -5.76% -50.70 $227.59M 0.00%

About VNDA

VNDA is led by CEO Mihael H. Polymeropoulos, employs 368 people, headquartered in US, publicly traded since 2006.

VNDA stock trades at $5.22 with a market capitalization of $313.91M. The stock is valued at a price-to-earnings (P/E) ratio of -1.65, price-to-book of 1.14, price-to-sales of 1.71. Over the past 52 weeks the stock has ranged between $4.14 and $9.94, and currently trades 47.5% below its 52-week high.

On profitability, VNDA generates a return on equity (ROE) of -67.28%, return on capital employed of -46.18%, an operating margin of -69.91%, a net profit margin of -1.10%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides